Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07258459
Recruiting Observational

Two Previous Cesarean and Vaginal Birth Before and After Starting Training and Protocols

NCT07258459 · tracked via the Priya Life Science Italy tracker
Sponsor
G. d'Annunzio University
Phase
Observational
Started
2016-01-01
Last updated
2025-12-02

Condition(s) studied

Cesarean Delivery Affecting Fetus or NewbornLabor (Obstetrics)--ComplicationsHemorrhagic Complications

Investigational drug(s) / intervention(s)

Acceptance, rate of vaginal birth and safety

Acceptance, rate of vaginal birth and safety: In 2021 started a new delivery protocol enhancing the opportunity of having a trial of labor in women with a history of two previous CS. Rate of acceptance, rate of successful vaginal birth, maternal and fetal outcomes were evaluated

Study summary

In 2015 ObGyn Dept of Santo Spirito Hospital in Pescara (Italy) started protocol for previous CS vaginal birth. In 2021 was started a protocol for training on obstetric emergencies and protocol on two previous cesarean was endorsed. Patients attending birth in Pescara with two previous from january 2016 to December 2020, and from january 2021 to december 2025 were collected. A different counseling approach was adopted from 2021. Women's acceptance of trial of labor and maternal and fetal outcomes were collected.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * pregnant women * pregnancy above 34 weeks' gestation * cephalic presentation of the fetus * singleton and twins * diamniotic twins * 2 previous CS * more than 18 months from last CS * no other indication to CS Exclusion Criteria: * pregnancy below 34 weeks' gestation * breech baby * triplets or high order multiple pregnancies * more than 2 previous CS * less than 18 months from last CS * precence of other indications to CS (i.e. maternal diseases, placenta previa, etc.)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Claudio Celentano Pescara PE Recruiting
Santo Spirito Hospital Pescara PE Recruiting

More G. d'Annunzio University trials in Italy

Predictive Role of the Full-mouth Plaque Score on the Outcomes of Non-surgical Periodontal Therapy. Starting soon
Biofeedback Based System to Enhance Robotic Assisted Gait Training in Children With Cerebral Palsy Recruiting
Mindfulness-based Rehabilitation in a University Museum Setting to Reduce Pain and Improve Quality of Life in Women With Fibromyalgia: a Randomized Controlled Trial Recruiting
Optimizing Clinical Outcomes in CAF + SCTG: the Impact of Compressive Sutures Starting soon
Learning Curves of Different Devices for Vaginal Birth on Mannequin Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07258459 on ClinicalTrials.gov ↗ ← All trials in Italy